Česky English

+420 511 181 555

info@iccti.eu

2nd ANNUAL CONFERENCE OF ICCTI

2nd ANNUAL CONFERENCE OF ICCTI

IMMUNOTHERAPY AND CELL THERAPY CLINICAL TRIALS

November 15 – 16, 2012
Hotel Myslivna, Brno, Czech Republic

Day 1, November 15, 2012
8:00 – 8:50 Registration
8:50 – 9:00 Opening of the conference – Jaroslav Michalek
Section A Chair: Jaroslav Michalek
9:00 – 9:30 Jaroslav Michalek
ICCTI activities and mission
9:30 – 10:00 Catherine Bollard
T cell Therapy for Lymphoma
10:00 – 10:30 John Barrett
Leukemia-antigen specific T cells to prevent or treat relapse of myeloid malignancies
10:30 – 11:00 Coffee break
Section B Chair: Catherine Bollard
11:00 – 11:30 Virgil Schijns
Impact of innate immune system stimulation during multimodular immunotherapy against glioblastoma
11:30 – 12:00 Kingston Mills
Immunotherapeutics and vaccines approaches to cancer based on manipulating regulatory and effector T cells by targeting dendritic cells
12:00 – 12:30 Thomas Felzmann
A randomised multi-centre phase II study for the treatment of patients suffering from Glioblastoma Multiforme with a dendritic cell-based cancer vaccine
12:30 – 14:30 Lunch break
14:30 – 15:30 Round Table Discussion (Section A)
J. Michalek, C. Bollard, J. Barrett, V. Schijns, K. Mills, T. Felzmann
15:30 – 16:30 Round Table Discussion (Section B)
J. Michalek, P. Kudela, D. Powell, A. Stathopoulos, Y. Godfrin, E. Smits, M. Foti
Day 2, November 16, 2012
8:45 – 9:00 Registration
Section A Chair: Yann Godfrin
9:00 – 9:30 Pavol Kudela
Bacterial ghosts as tumor antigen delivery system for dendritic cell-based cancer immunotherapy
9:30 – 10:00 Daniel J. Powell Jr.
Innovative approaches to adoptive T cell therapy
10:00 – 10:30 Apostolos Stathopoulos
Report of ERC-1671 (Gliovac) vaccine use in recurrent GBM patients
10:30 – 11:00 Coffee break
Section B Chair: Daniel J. Powell Jr.
11:00 – 11:30 Yann Godfrin
The red blood cell as a new drug formulation – pre clinical and clinical overview
11:30 – 12:00 Evelien Smits
Immunotherapeutic clinical cell therapy trials using mRNA-electroporated dendritic cells
12:00 – 12:30 Maria Foti
Development of cell-based molecular signatures for quality controls of dendritic cells therapies
12:30 – 14:30 Lunch break
14:30 – 15:30 Round Table Discussion (Section A)
J. Michalek, C. Bollard, J. Barrett, V. Schijns, K. Mills, T. Felzmann
15:30 – 16:30 Round Table Discussion (Section B)
J. Michalek, P. Kudela, D. Powell, A. Stathopoulos, Y. Godfrin, E. Smits, M. Foti
16:30 – 16:45 Closing remarks – Jaroslav Michalek

© 2017 ICCTI. Mezinárodní konsorcium pro buněčnou terapii a imunoterapii | registrační číslo projektu: CZ.1.07/2.3.00/20.0012